News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
704,183 Results
Type
Article (40379)
Company Profile (247)
Press Release (663557)
Multimedia
Podcasts (51)
Webinars (12)
Section
Business (205264)
Career Advice (2009)
Deals (35588)
Drug Delivery (95)
Drug Development (81271)
Employer Resources (172)
FDA (16374)
Job Trends (14916)
News (346946)
Policy (32720)
Tag
Academia (2582)
Accelerated approval (5)
Adcomms (21)
Allergies (86)
Alliances (49629)
ALS (93)
Alzheimer's disease (1382)
Antibody-drug conjugate (ADC) (132)
Approvals (16368)
Artificial intelligence (263)
Autoimmune disease (22)
Automation (16)
Bankruptcy (361)
Best Places to Work (11673)
BIOSECURE Act (19)
Biosimilars (106)
Biotechnology (175)
Bladder cancer (78)
Brain cancer (28)
Breast cancer (292)
Cancer (2313)
Cardiovascular disease (180)
Career advice (1678)
Career pathing (30)
CAR-T (153)
Cell therapy (433)
Cervical cancer (20)
Clinical research (66242)
Collaboration (854)
Company closure (2)
Compensation (558)
Complete response letters (20)
COVID-19 (2591)
CRISPR (41)
C-suite (250)
Cystic fibrosis (102)
Data (2302)
Decentralized trials (2)
Denatured (19)
Depression (44)
Diabetes (275)
Diagnostics (6391)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (120)
Drug pricing (102)
Drug shortages (25)
Duchenne muscular dystrophy (96)
Earnings (87495)
Editorial (39)
Employer branding (21)
Employer resources (146)
Events (113374)
Executive appointments (739)
FDA (17745)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (766)
Gene editing (109)
Generative AI (19)
Gene therapy (310)
GLP-1 (717)
Government (4437)
Grass and pollen (4)
Guidances (150)
Healthcare (19075)
Huntington's disease (24)
IgA nephropathy (27)
Immunology and inflammation (121)
Indications (29)
Infectious disease (2735)
Inflammatory bowel disease (144)
Inflation Reduction Act (8)
Influenza (52)
Intellectual property (98)
Interviews (312)
IPO (16593)
IRA (40)
Job creations (3648)
Job search strategy (1423)
Kidney cancer (10)
Labor market (43)
Layoffs (476)
Leadership (17)
Legal (7957)
Liver cancer (78)
Lung cancer (325)
Lymphoma (156)
Machine learning (9)
Management (58)
Manufacturing (322)
MASH (73)
Medical device (13688)
Medtech (13693)
Mergers & acquisitions (19564)
Metabolic disorders (702)
Multiple sclerosis (82)
NASH (16)
Neurodegenerative disease (91)
Neuropsychiatric disorders (27)
Neuroscience (1932)
NextGen: Class of 2025 (6566)
Non-profit (4504)
Now hiring (40)
Obesity (371)
Opinion (204)
Ovarian cancer (80)
Pain (97)
Pancreatic cancer (89)
Parkinson's disease (150)
Partnered (21)
Patents (241)
Patient recruitment (115)
Peanut (46)
People (57615)
Pharmaceutical (63)
Pharmacy benefit managers (19)
Phase I (20633)
Phase II (29186)
Phase III (21733)
Pipeline (1344)
Policy (146)
Postmarket research (2571)
Preclinical (8769)
Press Release (64)
Prostate cancer (107)
Psychedelics (30)
Radiopharmaceuticals (247)
Rare diseases (384)
Real estate (5945)
Recruiting (65)
Regulatory (22451)
Reports (47)
Research institute (2331)
Resumes & cover letters (349)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (71)
Series A (131)
Series B (87)
Service/supplier (11)
Sickle cell disease (52)
Special edition (16)
Spinal muscular atrophy (147)
Sponsored (29)
Startups (3608)
State (2)
Stomach cancer (13)
Supply chain (69)
Tariffs (48)
The Weekly (30)
Vaccines (698)
Venture capitalists (42)
Weight loss (236)
Women's health (36)
Worklife (16)
Date
Last 7 days (931)
Last 30 days (2964)
Last 365 days (32462)
2025 (11720)
2024 (35357)
2023 (40264)
2022 (51386)
2021 (55916)
2020 (54337)
2019 (46829)
2018 (35277)
2017 (32345)
2016 (31762)
2015 (37809)
2014 (31528)
2013 (26584)
2012 (28829)
2011 (29478)
2010 (27574)
Location
Africa (721)
Alabama (54)
Alaska (7)
Arizona (233)
Arkansas (13)
Asia (38240)
Australia (6235)
California (6388)
Canada (2059)
China (533)
Colorado (272)
Connecticut (279)
Delaware (156)
Europe (82056)
Florida (946)
Georgia (213)
Idaho (57)
Illinois (549)
India (25)
Indiana (319)
Iowa (11)
Japan (171)
Kansas (106)
Kentucky (24)
Louisiana (11)
Maine (62)
Maryland (921)
Massachusetts (4742)
Michigan (224)
Minnesota (404)
Mississippi (2)
Missouri (87)
Montana (27)
Nebraska (25)
Nevada (67)
New Hampshire (67)
New Jersey (1798)
New Mexico (28)
New York (1797)
North Carolina (998)
North Dakota (8)
Northern California (2814)
Ohio (208)
Oklahoma (14)
Oregon (35)
Pennsylvania (1417)
Puerto Rico (13)
Rhode Island (34)
South America (1101)
South Carolina (25)
South Dakota (1)
Southern California (2403)
Tennessee (105)
Texas (945)
United States (23952)
Utah (189)
Virginia (153)
Washington D.C. (64)
Washington State (562)
West Virginia (3)
Wisconsin (56)
704,183 Results for "minerva surgical inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Minerva Surgical Reports Third Quarter 2023 Financial Results
Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a women’s health company focused on solutions to meet the distinct uterine healthcare needs of women, today reported third quarter financial results for the period ended September 30, 2023.
November 13, 2023
·
10 min read
Press Releases
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates
February 26, 2025
·
7 min read
Business
Minerva Surgical Reports Second Quarter 2023 Financial Results
Minerva Surgical, Inc. reported second quarter financial results for the period ended June 30, 2023.
August 2, 2023
·
10 min read
Business
Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates
Minerva Neurosciences, Inc. today reported business updates and financial results for the first quarter of 2024 ending March 31, 2024.
May 1, 2024
·
6 min read
Business
Minerva Surgical Reports First Quarter 2023 Financial Results
Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company) today reported first quarter financial results for the period ended March 31, 2023.
May 2, 2023
·
10 min read
Drug Development
Minerva’s Schizophrenia Candidate Rejected by FDA in Complete Response Letter
The FDA has rejected Minerva Neurosciences’ treatment for negative symptoms in schizophrenia, noting a lack of data and other factors that led to the Complete Response Letter.
February 27, 2024
·
2 min read
·
Tyler Patchen
Business
Minerva Surgical Announces the Appointment of Kaile Zagger as Chief Commercial Officer
Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical), a women’s health company focused on solutions to meet the distinct uterine healthcare needs of women, announced today the appointment of Kaile Zagger as its new Chief Commercial Officer.
March 21, 2023
·
4 min read
Business
Minerva Surgical to Announce First Quarter 2023 Financial Results
Minerva Surgical, Inc., a medical technology company focused on solutions to meet the distinct uterine healthcare needs of women, announced that it will release its first quarter 2023 financial results on Tuesday, May 2, 2023.
April 18, 2023
·
1 min read
Business
Minerva Surgical Reports Fourth Quarter and Full-Year 2022 Financial Results
Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a woman’s health company focused on solutions to meet the distinct uterine healthcare needs of women, today reported fourth quarter and full-year financial results for the period ended December 31, 2022.
March 21, 2023
·
12 min read
Press Releases
Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates
November 5, 2024
·
6 min read
1 of 70,419
Next
